

February 6, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Outcome of Board Meeting held on February 6, 2020.

The Board of Directors of the Company at its meeting held today, February 6, 2020, has inter alia, transacted the following businesses:


1. Approved the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
2. Approved a Second Interim Dividend @ 175% i.e Rs.1.75 (Rupee one and paise seventy five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2019-20. The Company has fixed **February 18, 2020** as the **Record Date** for the purpose of payment of Second Interim Dividend and the same will be paid on or before **March 2, 2020**.

We enclose a copy of the Press Release on Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2019.

The Board meeting commenced at 3.00 p.m and concluded at 6.00 p.m.

Yours faithfully,

For **AUROBINDO PHARMA LIMITED**


B. Adi Reddy
Company Secretary

Enclosures: as above.

